Sethera Therapeutics
Sethera Therapeutics develops next-generation peptide drugs using a proprietary enzymatic cross-linking technology to make highly stable polymacrocyclic peptides. Their pMCP Discovery Platform supports library creation, AI-powered data generation, and noncanonical building blocks, enabling partners in pharma and research institutions to discover and optimize peptide therapeutics. The core technology includes a cyclization enzyme that site-specifically installs thioether bonds, enabling up to six macrocycles per peptide. The platform integrates AI, mRNA display, phage display, and DNA-encoded libraries to explore diverse sequence-structure space and tailor architectures for challenging targets. Sethera seeks partnerships and licensing with pharmaceutical companies to bring novel therapies to market.
Sethera Therapeutics
Sethera Therapeutics develops next-generation peptide drugs using a proprietary enzymatic cross-linking technology to make highly stable polymacrocyclic peptides. Their pMCP Discovery Platform supports library creation, AI-powered data generation, and noncanonical building blocks, enabling partners in pharma and research institutions to discover and optimize peptide therapeutics. The core technology includes a cyclization enzyme that site-specifically installs thioether bonds, enabling up to six macrocycles per peptide. The platform integrates AI, mRNA display, phage display, and DNA-encoded libraries to explore diverse sequence-structure space and tailor architectures for challenging targets. Sethera seeks partnerships and licensing with pharmaceutical companies to bring novel therapies to market.